|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| HYPNOTIC/SEDATIVE/ANXIOLYTIC DRUGS, MISCELLANEOUS | | | | NO. | |
| PURPOSE:  To provide guidelines in regard to use of Miscellaneous Hypnotic/Sedative/Anxiolytic Drugs.  STATEMENT OF POLICY:  It is the policy of this facility that Miscellaneous Hypnotic/Sedative/Anxiolytic Drugs will not be initiated in any dose for any resident except when meeting the criteria for exception.  PROCEDURE:   1. Procedure for evaluation the use of Miscellaneous Hypnotic/Sedative/Anxiolytic Drugs.   Barbiturates (Examples)  GENERIC BRAND  Amobarbital (Amytal)  Butabarital (Butisol, others)  Pentobarbital (Nembutal)  Secobarbital (Seconal)  Phenobarbital (Many Brands)  Amobarbital-Secobarbital (Tuinal)  Barbiturates with other drugs (e.g., Fiorinal)  Miscellaneous Hypnotic/Sedative/Anxiolytic  GENERIC BRAND  Glutethimide (Doriden)  Methprylon (Noludar)  Ethchlorvynol (Placidyl)  Meprobamate (Equanil, Miltown)  Paraldehyde ( Many Brands)   1. Drugs with this category should not be INITIATED in the facility unless meeting the following exceptions: 2. Any sedative drug is an exception when used as a single dose sedative for dental or medical procedures. 3. Phenobarbital is an exception when used in the treatment of seizure disorders. 4. When drugs from this category are used, they may be unnecessary drugs as a result of inadequate indications for use. 5. Residents currently using these drugs or residents admitted to the facility while using these drugs should receive GRADUAL dose reductions. | | | | | |
| Approved: | Effective Date: | Revision Date: | Change No.: | | Page:  1 OF 2 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| HYPNOTIC/SEDATIVE/ANXIOLYTIC DRUGS, MISCELLANEOUS | | | | NO. | |
| 1. A GRADUAL dose reduction should be attempted at least twice within one year before one can conclude that the GDR is clinically contraindicated. 2. Newly admitted residents using these drugs may have a period of adjustment before a GRADUAL dose reduction is attempted. 3. Do not encourage rapid withdrawal of these drugs, as this might result in severe physiological withdrawal symptoms. 4. DOUMENTATION 5. Information regarding the use of drugs in this category should be recorded in the following areas: 6. Resident Care Plan 7. Pharmacy Consultation Report 8. Physician and Nursing Progress Notes 9. QA Auditing Form 10. Behavior Documentation   ATTACHMENT:  Hypnotic/Sedative/Anxiolytic Drugs Training | | | | | |
| Approved: | Effective Date: | Revision Date: | Change No.: | | Page:  2 OF 2 |